Cancer Biomarkers Market by Biomarker Type (Genetic, Protein), Cancer Type (Blood Cancer, Breast Cancer, Colorectal Cancer), Technology, Application, End User - Global Forecast 2023-2030
The Cancer Biomarkers Market is projected to reach USD 47.46 billion by 2030 from USD 18.98 billion in 2022, at a CAGR of 12.13% during the forecast period.
Market Segmentation & Coverage:
This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Cancer Biomarkers Market.
- Based on Biomarker Type, market is studied across Genetic and Protein. The Genetic is projected to witness significant market share during forecast period.
- Based on Cancer Type, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Skin Cancer, and Stomach Cancer. The Breast Cancer is projected to witness significant market share during forecast period.
- Based on Technology, market is studied across Bioinformatics, Cytogenetics, Imaging Technology, Immunoassays, and OMICS Technology. The Bioinformatics is projected to witness significant market share during forecast period.
- Based on Application, market is studied across Diagnostics, Drug Discovery & Development, Prognostics, and Risk Assessment. The Diagnostics is projected to witness significant market share during forecast period.
- Based on End User, market is studied across Academic & Cancer Research Centers, Hospitals, and Speciality Centers. The Hospitals is projected to witness significant market share during forecast period.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.
The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix is an indispensable tool for assessing the Cancer Biomarkers Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.
Market Share Analysis:
The Market Share Analysis offers invaluable insights into the vendor landscape Cancer Biomarkers Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.
Key Company Profiles:
The report delves into recent significant developments in the Cancer Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Agilent Technologies, Inc., Asuragen, Inc., Bio-Rad Laboratories, Inc., bioMérieux SA, Bristol-Myers Squibb Company, Bruker Corporation, Charles River Laboratories International, Inc., Enzo Biochem, Inc., Epigenomics AG, Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., Hologic, Inc., Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., PerkinElmer, Inc., Pfizer Inc., QIAGEN N.V, Quest Diagnostics Incorporated, Siemens Healthcare GmbH, Sysmex Corporation, and Thermo Fisher Scientific Inc..
The report offers valuable insights on the following aspects:
- Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
- Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
- Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
- Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
- Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast for the Cancer Biomarkers Market?
- Which products, segments, applications, and areas hold the highest investment potential in the Cancer Biomarkers Market?
- What is the competitive strategic window for identifying opportunities in the Cancer Biomarkers Market?
- What are the latest technology trends and regulatory frameworks in the Cancer Biomarkers Market?
- What is the market share of the leading vendors in the Cancer Biomarkers Market?
- Which modes and strategic moves are suitable for entering the Cancer Biomarkers Market?
Note: PDF & Excel + Online Access - 1 Year
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Cancer Biomarkers Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Increasing prevalence of cancer disorders among population
- 5.1.1.2. Rising initiatives and awareness campaigns for early cancer detection
- 5.1.1.3. Growing healthcare infrastructure and healthcare spending
- 5.1.2. Restraints
- 5.1.2.1. High costs associated with research and development
- 5.1.3. Opportunities
- 5.1.3.1. Emergence of better biomarkers for detection of aggressive liver cancer
- 5.1.3.2. Robust research activities to introduce new biomarkers for early detection of lung cancer
- 5.1.4. Challenges
- 5.1.4.1. Complex and stringent regulatory compliances
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of COVID-19
- 5.5. Cumulative Impact of Russia-Ukraine Conflict
- 5.6. Cumulative Impact of High Inflation
- 5.7. Porter’s Five Forces Analysis
- 5.7.1. Threat of New Entrants
- 5.7.2. Threat of Substitutes
- 5.7.3. Bargaining Power of Customers
- 5.7.4. Bargaining Power of Suppliers
- 5.7.5. Industry Rivalry
- 5.8. Value Chain & Critical Path Analysis
- 5.9. Regulatory Framework
- 5.10. Client Customization
- 6. Cancer Biomarkers Market, by Biomarker Type
- 6.1. Introduction
- 6.2. Genetic
- 6.3. Protein
- 7. Cancer Biomarkers Market, by Cancer Type
- 7.1. Introduction
- 7.2. Blood Cancer
- 7.3. Breast Cancer
- 7.4. Colorectal Cancer
- 7.5. Lung Cancer
- 7.6. Ovarian Cancer
- 7.7. Prostate Cancer
- 7.8. Skin Cancer
- 7.9. Stomach Cancer
- 8. Cancer Biomarkers Market, by Technology
- 8.1. Introduction
- 8.2. Bioinformatics
- 8.3. Cytogenetics
- 8.4. Imaging Technology
- 8.5. Immunoassays
- 8.6. OMICS Technology
- 9. Cancer Biomarkers Market, by Application
- 9.1. Introduction
- 9.2. Diagnostics
- 9.3. Drug Discovery & Development
- 9.4. Prognostics
- 9.5. Risk Assessment
- 10. Cancer Biomarkers Market, by End User
- 10.1. Introduction
- 10.2. Academic & Cancer Research Centers
- 10.3. Hospitals
- 10.4. Speciality Centers
- 11. Americas Cancer Biomarkers Market
- 11.1. Introduction
- 11.2. Argentina
- 11.3. Brazil
- 11.4. Canada
- 11.5. Mexico
- 11.6. United States
- 12. Asia-Pacific Cancer Biomarkers Market
- 12.1. Introduction
- 12.2. Australia
- 12.3. China
- 12.4. India
- 12.5. Indonesia
- 12.6. Japan
- 12.7. Malaysia
- 12.8. Philippines
- 12.9. Singapore
- 12.10. South Korea
- 12.11. Taiwan
- 12.12. Thailand
- 12.13. Vietnam
- 13. Europe, Middle East & Africa Cancer Biomarkers Market
- 13.1. Introduction
- 13.2. Denmark
- 13.3. Egypt
- 13.4. Finland
- 13.5. France
- 13.6. Germany
- 13.7. Israel
- 13.8. Italy
- 13.9. Netherlands
- 13.10. Nigeria
- 13.11. Norway
- 13.12. Poland
- 13.13. Qatar
- 13.14. Russia
- 13.15. Saudi Arabia
- 13.16. South Africa
- 13.17. Spain
- 13.18. Sweden
- 13.19. Switzerland
- 13.20. Turkey
- 13.21. United Arab Emirates
- 13.22. United Kingdom
- 14. Competitive Landscape
- 14.1. FPNV Positioning Matrix
- 14.2. Market Share Analysis, By Key Player
- 14.3. Competitive Scenario Analysis, By Key Player
- 15. Competitive Portfolio
- 15.1. Key Company Profiles
- 15.1.1. Abbott Laboratories Inc.
- 15.1.2. Agilent Technologies, Inc.
- 15.1.3. Asuragen, Inc.
- 15.1.4. Bio-Rad Laboratories, Inc.
- 15.1.5. bioMérieux SA
- 15.1.6. Bristol-Myers Squibb Company
- 15.1.7. Bruker Corporation
- 15.1.8. Charles River Laboratories International, Inc.
- 15.1.9. Enzo Biochem, Inc.
- 15.1.10. Epigenomics AG
- 15.1.11. Eurofins Scientific SE
- 15.1.12. Exact Sciences Corporation
- 15.1.13. F. Hoffmann-La Roche Ltd.
- 15.1.14. GE HealthCare Technologies Inc.
- 15.1.15. Hologic, Inc.
- 15.1.16. Illumina, Inc.
- 15.1.17. Merck KGaA
- 15.1.18. Myriad Genetics, Inc.
- 15.1.19. PerkinElmer, Inc.
- 15.1.20. Pfizer Inc.
- 15.1.21. QIAGEN N.V
- 15.1.22. Quest Diagnostics Incorporated
- 15.1.23. Siemens Healthcare GmbH
- 15.1.24. Sysmex Corporation
- 15.1.25. Thermo Fisher Scientific Inc.
- 15.2. Key Product Portfolio
- 16. Appendix
- 16.1. Discussion Guide
- 16.2. License & Pricing
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook